Literature DB >> 6467655

Triploidy, partial mole and dispermy. An investigation of 12 cases.

S E Procter, E S Gray, J L Watt.   

Abstract

Twelve triploid abortuses were investigated to determine the origin of the additional haploid set and were retrospectively examined for the development of partial hydatidiform mole. Eight out of ten suitable triploids were diagnosed as partial mole. Dispermy was indicated as the cause of triploidy in 6 informative cases of which 3 were also partial moles. However, one diandric triploid had no features of partial mole. The problem of maternal cell contamination in triploids and the difficulty of diagnosing partial moles on pathological grounds alone are discussed.

Mesh:

Year:  1984        PMID: 6467655     DOI: 10.1111/j.1399-0004.1984.tb00787.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  5 in total

1.  Parental origin and phenotype of triploidy in spontaneous abortions: predominance of diandry and association with the partial hydatidiform mole.

Authors:  M V Zaragoza; U Surti; R W Redline; E Millie; A Chakravarti; T J Hassold
Journal:  Am J Hum Genet       Date:  2000-05-05       Impact factor: 11.025

2.  Triploidy arising from a first meiotic non-disjunction in a mother carrying a reciprocal translocation.

Authors:  L Rochon; M J Vekemans
Journal:  J Med Genet       Date:  1990-11       Impact factor: 6.318

3.  A partial hydatidiform mole with 2N/3N mosaicism identified by molecular analysis.

Authors:  Y Ikeda; Y Jinno; H Masuzaki; N Niikawa; T Ishimaru
Journal:  J Assist Reprod Genet       Date:  1996-10       Impact factor: 3.412

4.  Hydatidiform mole: genetic origin in polyploid conceptuses.

Authors:  L O Vejerslev; J Dissing; H E Hansen; H Poulsen
Journal:  Hum Genet       Date:  1987-05       Impact factor: 4.132

5.  Parental origin of triploidy in human fetuses: evidence for genomic imprinting.

Authors:  D E McFadden; L C Kwong; I Y Yam; S Langlois
Journal:  Hum Genet       Date:  1993-11       Impact factor: 4.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.